NAD+
Nicotinamide Adenine Dinucleotide
Cofactor for sirtuin and PARP enzymes implicated in DNA-repair and metabolic longevity programs. Available in 500 mg and 1000 mg sizes.
Anti-Aging & Longevity
Category
From $71.99
Price
Research
Grade
Price
From $71.99
✓ 10% off via PeptidesMuscle
Suggested Protocol
Clinical and research protocols uniformly use slow IV infusion — 500mg to 1g delivered over 2-4 hours via gravity drip or infusion pump. Rapid bolus administration is contraindicated in the published experience (acute chest pressure, anxiety, flushing). Weekly-to-monthly cadence depending on research design.
NAD+ sits in a peptide catalog for one reason: it shares research positioning with longevity peptides despite being a pyridine dinucleotide rather than an amino-acid polymer. Structurally it is nicotinamide and adenine linked through a pyrophosphate bridge across two ribose sugars — zero amino acid residues. It ends up next to GHK-Cu and epitalon because the research community probing cellular senescence, mitochondrial function, and sirtuin biology uses all three in overlapping protocols.
Not a Peptide
Why It Sits in a Peptide Catalog Anyway
NAD+ is a pyridine dinucleotide — nicotinamide, adenine, two riboses, a pyrophosphate bridge. No amino acid residues. Its inclusion alongside peptides reflects shared research positioning in the longevity and mitochondrial-biology communities rather than any chemical similarity. Evaluate it against the NR/NMN/NAD+ precursor literature, not against peptide pharmacology.
The Rate-Dependence Rule
Why 500mg Over 2 Hours and Not 2 Minutes
Identical 500mg dose delivered as a rapid bolus produces acute chest pressure, flushing, and anxiety-like symptoms that slow-infusion delivery avoids entirely. The mechanism is incompletely characterised but appears to involve rapid CD38-mediated NAD+ hydrolysis and autonomic activation when cellular uptake cannot keep pace with plasma loading. Rate is the more important variable than total dose.
The Three Enzyme Families
Where NAD+ Actually Goes Once Administered
Cellular NAD+ is consumed by sirtuin deacetylases (SIRT1-7), PARPs (DNA-damage-response enzymes), and CD38/CD157 ectoenzymes. Each family has distinct localisation and kinetic properties. Research endpoints differ depending on which family's substrate pool is rate-limiting in the tissue of interest — sirtuin-dependent endpoints respond differently than PARP-dependent ones.
Reported Outcomes
500mg single-session scale matches published clinical NAD+ infusion protocols
Direct NAD+ substrate — bypasses the NR/NMN biosynthetic conversion steps
Sirtuin, PARP, and CD38 enzyme substrate across the three major NAD+-consuming families
Clinical-replication research where NR/NMN precursor pharmacokinetics do not fit
Slow-infusion delivery window controls the adverse-effect profile
Non-peptide dinucleotide — catalog positioning reflects longevity-research adjacency
Specifications
| Product | NAD+ |
|---|---|
| Category | Anti-Aging & Longevity |
| Format | Lyophilized powder |
| Price | From $71.99 |
Ready to start?
From $71.99
✓ 10% off via PeptidesMuscle
Administration Outline
Clinical and research protocols uniformly use slow IV infusion — 500mg to 1g delivered over 2-4 hours via gravity drip or infusion pump. Rapid bolus administration is contraindicated in the published experience (acute chest pressure, anxiety, flushing). Weekly-to-monthly cadence depending on research design.
NAD+ — FAQs
More in Anti-Aging & Longevity
View All
Melanotan II 10mg
Melanotan II 10mg — the shorter, nonselective α-MSH analog from the same University of Arizona program that produced afamelanotide, the precursor molecule that PT-141 was deliberately engineered to improve upon.
P21 10mg
P21 10mg — a short peptide derived from ciliary neurotrophic factor (CNTF), investigated in adult-hippocampal-neurogenesis research as a non-mitogenic fragment that triggers CNTF-receptor signaling for memory-formation endpoints.
